The investment at Upper Merion in Pennsylvania creates a technologically-advanced manufacturing hub that offers the flexibility and speed necessary when making today’s complex specialty medicines. The expansion of the biopharmaceutical facility will help deliver new medicines for cancer and other diseases to patients faster.
Emma Walmsley, Chief Executive Officer at GSK commented: “These investments will support and accelerate the transformation of our pipeline to deliver the next generation of medicines and vaccines for patients who need them. This also underscores GSK’s longstanding commitment to making innovative medicines and vaccines here in the US.”
